[Advances in the treatment of thrombotic thrombocytopenic purpura].
作者信息
Wang X Y, Yang R C
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1055-1059. doi: 10.3760/cma.j.issn.0253-2727.2019.12.020.
Abstract
摘要
相似文献
1
[Advances in the treatment of thrombotic thrombocytopenic purpura].[血栓性血小板减少性紫癜的治疗进展]
Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1055-1059. doi: 10.3760/cma.j.issn.0253-2727.2019.12.020.
2
Current management of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的当前管理
Curr Opin Hematol. 2008 Sep;15(5):445-50. doi: 10.1097/MOH.0b013e328309ec62.
3
A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.一例以妊娠期血栓性血小板减少性紫癜为表现的严重ADAMTS13缺乏症病例。
Med Pregl. 2012 Sep-Oct;65(9-10):436-9. doi: 10.2298/mpns1210436n.
4
Thrombotic thrombocytopenic purpura: The role of ADAMTS13.血栓性血小板减少性紫癜：ADAMTS13 的作用。
Cleve Clin J Med. 2016 Aug;83(8):597-603. doi: 10.3949/ccjm.83a.15009.
5
Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.孕期表现为免疫性血小板减少性紫癜的遗传性血栓性血小板减少性紫癜：一例报告
J Med Case Rep. 2018 Jan 22;12(1):15. doi: 10.1186/s13256-017-1545-3.
6
An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.获得性血栓性血小板减少性紫癜的发病机制与治疗进展
Curr Opin Neurol. 2003 Jun;16(3):367-73. doi: 10.1097/01.wco.0000073939.19076.78.
7
Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.血栓性血小板减少性紫癜：超越经验主义和血浆置换。
Am J Med. 2019 Sep;132(9):1032-1037. doi: 10.1016/j.amjmed.2019.03.009. Epub 2019 Mar 28.
8
Understanding therapeutic targets in thrombotic thrombocytopenic purpura.了解血栓性血小板减少性紫癜的治疗靶点。
Intensive Care Med. 2017 Sep;43(9):1398-1400. doi: 10.1007/s00134-016-4662-3. Epub 2017 Jan 23.
9
Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.临床预测评分对血栓性血小板减少性紫癜的独立队列中的表现。
Vox Sang. 2013 Nov;105(4):313-8. doi: 10.1111/vox.12050. Epub 2013 May 11.
10
Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?检测疑似血栓性血小板减少性紫癜患者的ADAMTS13活性：何时、如何以及为何进行检测？
Transfusion. 2015 Jan;55(1):11-3. doi: 10.1111/trf.12885.
本文引用的文献
1
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.预测免疫性血栓性血小板减少性紫癜复发的因素及利妥昔单抗的疗效。
Blood Adv. 2019 May 14;3(9):1512-1518. doi: 10.1182/bloodadvances.2019031039.
2
Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜的临床药理学。
Expert Rev Clin Pharmacol. 2019 Jun;12(6):537-545. doi: 10.1080/17512433.2019.1607293. Epub 2019 Apr 28.
3
Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura.卡泊单抗在一名难治性血栓性血小板减少性紫癜儿童中的应用。
Pediatr Blood Cancer. 2019 Jul;66(7):e27737. doi: 10.1002/pbc.27737. Epub 2019 Mar 29.
4
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.先天性血栓性血小板减少性紫癜的特征与治疗。
Blood. 2019 Apr 11;133(15):1644-1651. doi: 10.1182/blood-2018-11-884700. Epub 2019 Feb 15.
5
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.
6
Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission.给予化脓性链球菌免疫球蛋白G降解酶（IdeS）用于临床缓解期血栓性血小板减少性紫癜患者中持续存在的抗ADAMTS13抗体。
Br J Haematol. 2019 Jul;186(1):137-140. doi: 10.1111/bjh.15706. Epub 2018 Nov 29.
7
Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.输注载有重组 ADAMTS13（一种具有血小板反应素 1 型重复的解整合素和金属蛋白酶）的血小板可有效抑制与血栓性血小板减少性紫癜相关的动脉血栓形成。
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2731-2743. doi: 10.1161/ATVBAHA.118.311407.
8
Caplacizumab: First Global Approval.卡普拉珠单抗：全球首次获批。
Drugs. 2018 Oct;78(15):1639-1642. doi: 10.1007/s40265-018-0989-0.
9
Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series.自身免疫性血栓性血小板减少性紫癜背景下的补体调节基因突变：病例系列
Mayo Clin Proc Innov Qual Outcomes. 2017 Dec 20;2(1):69-73. doi: 10.1016/j.mayocpiqo.2017.11.004. eCollection 2018 Mar.
10
Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience.长春新碱作为血栓性血小板减少性紫癜治疗性血浆置换的辅助治疗：单中心经验。
Balkan Med J. 2018 Nov 15;35(6):417-421. doi: 10.4274/balkanmedj.2017.1215. Epub 2018 Jul 3.
Zotero 插件